xxvi
Comprehensive Integration Platform with Connectors and APIs
LabWare provides a comprehensive Integration Platform consisting of connectors and integral API capabilities. This enables the seamless integration and exchange of data between LabWare, your laboratory instrumentation, as well as business systems. This simplifies the integration process, delivering a built-in solution for automation.
The LabWare integration platform utilises LabWare’s powerful configuration tools and industry standard protocols. This ensures improvements in efficiency, compliance, and data integrity are delivered whilst reducing implementation and support costs. Beneficially, the LabWare Integration platform provides the ability to integrate instrumentation and systems both cloud-based and on-premise within the single fully integrated and compliant LabWare Enterprise Laboratory platform.
LabWare’s Integration Platform solution is the result of over 30 years of experience working with over 2,500 companies worldwide using LabWare systems in a wide range of industries
More information online:
ilmt.co/PL/1X4p 59753pr@reply-direct.com
Industry-first IVDR-Compliant Reagents for Flow Cytometry
To help laboratories prepare for the upcoming In Vitro Diagnostic Medical Devices Regulation (IVDR) and to clear up any confusion, Beckman Coulter Life Sciences has achieved an industry-first by offering more than 270 reagents for flow cytometry that are IVDR compliant and available immediately. This is three years ahead of the May 2024 deadline set by the European Union. The company has also expanded its network of certified manufacturing sites to include locations in France, Ireland, China, India, and the United States to meet demand.
The IVDR is designed to ensure that in vitro diagnostic products achieve the highest levels of safety and efficiency, replacing the In Vitro Diagnostics Directive (98/79/EC) (IVDD) that has been in effect since 1993. The change will heavily impact labs using Laboratory-Developed Tests (LDTs) or ‘in-house IVDs’, which are the majority of clinical flow cytometry tests. With the May 2024 deadline approaching, Beckman Coulter Life Sciences is providing a resource guide that includes eBooks, whitepapers, FAQs, and the opportunity to request a consultation with an expert.
Dr Andreas Böehmler, Director of Clinical Solutions Product Management for the Global Flow Cytometry Business Unit, emphasised that making the necessary changes to become IVDR compliant can take several months or more to successfully implement, so it is critical to start the process now to avoid potential and costly laboratory shutdowns.
Beckman Coulter Life Sciences is one of the few reagent providers to achieve listing status on the official European Database on Medical Devices (EUDAMED), with its IVDR portfolio searchable under its listed manufacturing site in Marseille, Immunotech SAS.
As the deadline for LDTs or ‘in-house IVDs’ approaches, industry leaders agree that now is the time to begin examining laboratory needs to ensure IVDR compliance.
Beckman Coulter Life Sciences’ IVDR-compliant single-colour antibodies are intended to be used in conjunction with other antibodies for multicolour panel design and can be used for diagnosis, monitoring, or prognosis of patients with haematological abnormalities, neoplasms, disorders, immunodeficiencies, or autoimmune disease. Product availability may vary across regions outside the EU, including China, India, Japan, and countries that accept the CE mark.
More information online:
ilmt.co/PL/p1ew 60239pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148 |
Page 149 |
Page 150 |
Page 151 |
Page 152 |
Page 153 |
Page 154 |
Page 155 |
Page 156 |
Page 157 |
Page 158 |
Page 159 |
Page 160 |
Page 161 |
Page 162 |
Page 163 |
Page 164 |
Page 165 |
Page 166 |
Page 167 |
Page 168 |
Page 169 |
Page 170 |
Page 171 |
Page 172 |
Page 173 |
Page 174 |
Page 175 |
Page 176 |
Page 177 |
Page 178 |
Page 179 |
Page 180 |
Page 181 |
Page 182 |
Page 183 |
Page 184 |
Page 185 |
Page 186 |
Page 187 |
Page 188
